Peter E. Carson
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
2020/08/28 by Milton Packer, Stefan D. Anker, Javed Butler +36 · 49 citations
Medicine · #Diabetes Treatment and Management #Hyperglycemia and glycemic control in critically ill and hospitalized patients #Renal Transplantation Outcomes and Treatments
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
2021/08/27 by Stefan D. Anker, Javed Butler, Gerasimos Filippatos +38 · 46 citations
Medicine · #Diabetes Treatment and Management #Hyperglycemia and glycemic control in critically ill and hospitalized patients #Pancreatic function and diabetes
- Effect of Valsartan Added to Background ACE Inhibitor Therapy in Patients with Heart Failure: Results from Val-HeFT
2004/12/01 by Henry Krum, Peter E. Carson, Csaba Farsang +5 · 3 citations
Medicine · #Heart Failure Treatment and Management #Cardiac, Anesthesia and Surgical Outcomes #Atrial Fibrillation Management and Outcomes
- Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
1994/12/01 by Jeffrey L. Anderson, Edward V. Platia, Alfred P. Hallstrom +4 · 1 citation
Medicine · #Cardiac electrophysiology and arrhythmias #Cardiac Arrhythmias and Treatments #Cardiac Arrest and Resuscitation #Medicine #Flecainide #Internal medicine #Myocardial infarction #Cardiology #Ejection fraction #Placebo #QT interval #Anesthesia #Hazard ratio #Sudden cardiac death #Heart failure #Confidence interval #Atrial fibrillation